文献速递糖尿病

循环CD34+及CD34+CD133+干细胞对2型糖尿病患者心血管结局的长期预测

Long-term Prediction of Cardiovascular Outcomes by Circulating CD34+ and CD34+CD133+ Stem Cells in Patients With Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2016-11-04

该队列纳入187例2型糖尿病患者,中位随访6.1年,评估基线6种干/祖细胞表型对首次心血管事件的预测能力。48例发生主要结局(4.5/100患者年);CD34+降低(HR 2.21,95%CI 1.14-4.29)与CD34+CD133+降低(HR 2.98,95%CI 1.46-6.08)独立预测未来事件,加入CD34+可改善风险区分。

要点

  • 187例2型糖尿病患者中位随访6.1年,48例发生首次心血管事件(4.5/100患者年)。
  • 发生事件者基线CD34+与CD34+CD133+细胞显著低于未发生者。
  • CD34+降低(HR 2.21)与CD34+CD133+降低(HR 2.98)独立预测未来心血管事件。

核心结论

  • 在2型糖尿病患者中,基线循环CD34+干细胞水平降低可预测长达6年后的不良心血管结局,并改善风险分层。

研究设计与样本

  • 队列研究,纳入187例2型糖尿病患者,中位随访6.1年。
  • 基线检测外周血中基于CD34、CD133和KDR表达的6种干/祖细胞表型。

主要发现

  • 主要结局在48例患者中发生(4.5/100患者年)。
  • 发生心血管事件的患者CD34+和CD34+CD133+细胞显著低于未发生者。
  • CD34+和CD34+CD133+低于中位水平者心血管事件发生率更高。
  • Cox回归中,CD34+降低(HR 2.21,95%CI 1.14-4.29)与CD34+CD133+降低(HR 2.98,95%CI 1.46-6.08)独立预测未来事件。
  • 将CD34+细胞计数加入参考模型或UK Prospective Diabetes Study风险引擎后,C统计量、连续净重分类改善和/或综合判别指数改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cardiovascular risk varies substantially in the population with diabetes, and biomarkers can improve risk stratification. Circulating stem cells predict future cardiovascular events and death, but data for the population with diabetes are scant. In this study we evaluated the ability of circulating stem cell levels to predict future cardiovascular outcomes and improve risk discrimination in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A cohort of 187 patients with type 2 diabetes was monitored for a median of 6.1 years. The primary outcome was time to a first cardiovascular event, defined as 3-point major adverse cardiovascular event (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) plus hospitalization for cardiovascular causes. At baseline, we measured six stem/progenitor cell phenotypes in peripheral blood based on expression of CD34, CD133, and KDR. RESULTS: The primary outcome occurred in 48 patients (4.5/100 patient-years). Patients with incident cardiovascular events had significantly lower CD34+ and CD34+CD133+ cells than those without. Higher rates of cardiovascular events occurred in patients with below median levels of CD34+ and CD34+CD133+. In Cox proportional hazards regression analyses, a reduced CD34+ (hazard ratio 2.21 [95% CI 1.14-4.29]) and CD34+CD133+ (2.98 [1.46-6.08]) cell count independently predicted future events. Addition of the CD34+ cell count to the reference model or the UK Prospective Diabetes Study risk engine improved C statistics, continuous net reclassification improvement, and/or integrated discrimination index. CONCLUSIONS: In patients with type 2 diabetes, a reduced baseline level of circulating CD34+ stem cells predicts adverse cardiovascular outcomes up to 6 years later and improves risk stratification.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Fadini GP, Rigato M, Cappellari R, et al. Long-term Prediction of Cardiovascular Outcomes by Circulating CD34+ and CD34+CD133+ Stem Cells in Patients With Type 2 Diabetes. Diabetes Care. 2016. PMID: 27815289. doi:10.2337/dc16-1755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。